‘Global healthcare M&A to recover this year... AI-China’
By Cha, Jihyun | translator Alice Kang
25.01.15 05:00:57
가나다라
0
131 life sciences M&A deals made in 2024 - average deal size USD 1 billion
“M&A expected to pick up gradually in 2025, but some regulatory and policy concerns remain”
Life sciences companies seek growth opportunities in emerging AI fields and collaboration with China
Artificial intelligence (AI) and China are expected to be the keywords for mergers and acquisitions (M&A) in the global bio and healthcare sector this year.
On the 14th, KoreaBIO disclosed a report by global accounting consulting firm Ernst & Young (EY) that contained the prospects above.
According to the report, 130 M&A deals were made in the global bio-healthcare sector last year, including 95 for biopharmaceuticals and 36 for medical devices. This was similar to the previous year's 130 (81 biopharma and 49 medical devices).
Deal values were down significantly from the previous year. The value of M&A deals last year was USD 130 billion (approximately KRW 190 trillion), down
Cha, Jihyun(chaji@dailypharm.com)
If you want to see the full article, please JOIN US (click)